Search Results
Found 3 results
510(k) Data Aggregation
(194 days)
FIBERGRAFT BG Morsels
FIBERGRAFT™ BG Morsels - Bone Graft Substitute is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. FIBERGRAFT™ BG Morsels is indicated to be gently packed into bony voids or gaps of the skeletal system (i.e., posterolateral spine, extremities and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced with bone during the healing process. FIBERGRAFT™ BG Morsels must be used with autogenous bone marrow aspirate and autograft in the posterolateral spine.
FIBERGRAFT™ BG Morsels is not indicated for use in load-bearing applications; therefore, standard internal or external stabilization techniques must be followed to obtain rigid stabilization.
The FIBERGRAFT™BG Morsels provide an osteoconductive, resorbable, biocompatible bone graft substitute that is to be gently packed into defect sites. The FIBERGRAFT™BG Morsels are made from crystalline 45S5 bioactive glass. Each granule of BG Morsels is created from a matrix of bioactive glass fibers and microspheres. Bioactive glass is defined as a group of glasses that has a compositional range that allows the formation of hydroxyapatite (HA) as a surface layer when exposed to an aqueous phosphate-containing solution such as simulated body fluid. The HA layer that forms in an aqueous phosphate-containing solution plays a significant role in forming a strong bond with natural bone. The granules provide an ultra-porous scaffold for desired biological response and improved handling characteristics, while optimizing radiopacity and resorption. BG Morsels are generally spherical in appearance and provided in granular form. The matrix is flash sintered to form a porous shell at its surface, which creates the generally spherical structure of the granules, while maintaining a level of porosity within each granule.
The provided document is a 510(k) summary for a medical device called FIBERGRAFT™ BG Morsels - Bone Graft Substitute. It does not describe an AI/ML medical device, nor does it detail a study involving human readers or AI assistance.
Therefore, I cannot provide the requested information regarding acceptance criteria and study details for an AI/ML medical device's performance because the provided text is about a bone graft substitute, not an AI/ML product.
The document focuses on demonstrating substantial equivalence to a predicate device for a physical bone graft substitute, involving:
- Physical Property Evaluations: Simulated distribution, whole package integrity, seal strength, accelerated and real-time aging tests.
- Biocompatibility Testing: ISO 10993 testing.
- Animal Studies:
- Ovine Model: 58 skeletally mature sheep, evaluating device performance in critical sized cancellous bone defects (lateral distal femurs) over 24 weeks with interim evaluations (4, 8, 12, 24 weeks; min 3 animals/time point/group). Compared to positive control (predicate NovaBone Putty) and negative sham control (untreated defect). Data included radiographic, histological, histomorphometric, and biomechanical data.
- Rabbit Model: 41 skeletally mature rabbits, evaluating device performance in a posterolateral spine fusion model over 26 weeks. Compared to predicate device and autograft (positive) control. Data included radiographic, histological, histomorphometric, and biomechanical data.
- In Vitro Studies: Demonstrating apatite layer formation on the surface in simulated body fluid (SBF).
This information does not align with the specific questions about AI/ML device performance, ground truth establishment by experts, or MRMC studies.
Ask a specific question about this device
(26 days)
FIBERGRAFT BG MORSELS
FIBERGRAFT™ BG Morsels Bone Graft Substitute is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. FIBERGRAFT™ BG Morsels is indicated to be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone . The product provides a bone void filler that resorbs and is replaced with the healing process.
FIBERGRAFT™ BG Morsels is not indicated for use in load-bearing applications; therefore, standard internal or external stabilization techniques must be followed to obtain rigid stabilization.
FIBERGRAFT™ BG Morsels provides an osteoconductive, resorbable, biocompatible bone graft substitute made from crystalline 45S5 bioactive glass. Each granule of FIBERGRAFT™ BG Morsels is created from a matrix of bioactive glass fibers and microspheres. Bioactive glass is defined as a group of glasses which has a compositional range that allows the formation of hydroxyapatite (HA) as a surface layer when exposed to an aqueous phosphate-containing solution such as simulated body fluid. The HA layer that forms in an aqueous phosphate-containing solution plays a significant role in forming a strong bond with natural bone. The granules provide an ultra-porous scaffold for desired biological response and improved handling characteristics, while optimizing radiopacity and resorption. FIBERGRAFT™ BG Morsels are generally spherical in appearance and provided in granular form. The matrix is flash sintered to form a porous shell at its surface, which creates the generally spherical structure of the granules, while maintaining a level of porosity within each granule. The primary purpose of this submission is to add the option to use blood to mix with the product prior to implantation. Changes were also made to the product trade name and the labeled volume sizes.
Here's an analysis of the provided text regarding the acceptance criteria and study for the FIBERGRAFT™ BG Morsels Bone Graft Substitute:
Based on the provided 510(k) summary, the device under review is primarily a modification to a previously cleared device. Therefore, the "acceptance criteria" and "study" are focused on demonstrating that the modified device remains substantially equivalent to its predicate, particularly concerning the new addition of using blood as a mixing agent.
1. Table of Acceptance Criteria and Reported Device Performance
Acceptance Criteria Point | Reported Device Performance |
---|---|
Fluid Absorbability (with blood vs. saline) | "All test results were passing, supporting substantial equivalence of the modified device compared to the predicate device." (Implied: Fluid absorption with blood is comparable and acceptable). |
Device Packability (with blood) | "Device packability... characteristics were also observed during testing." (Implied: Packability with blood is acceptable and comparable). |
Handling Characteristics (with blood) | "Handling characteristics were also observed during testing." (Implied: Handling characteristics with blood are acceptable and comparable). |
Performance at Time Zero (of modified device) | "Testing was conducted at time zero... All test results were passing..." (Implied: Performance is acceptable immediately after mixing). |
Performance After Aging (of modified device) | "Testing was conducted... after aging. All test results were passing..." (Implied: Performance is maintained over time, consistent with predicate). |
No Changes to Product Composition | "No changes were made to the product composition..." (This is a direct statement, indicating adherence to predicate). |
No Changes to Packaging | "No changes were made to the... packaging..." (This is a direct statement, indicating adherence to predicate). |
No Changes to Sterility | "No changes were made to the... sterility..." (This is a direct statement, indicating adherence to predicate). |
No Changes to Biocompatibility | "No changes were made to the... biocompatibility as compared to the predicate device." (This is a direct statement, indicating adherence to predicate). |
Function as Intended without new safety/effectiveness questions | "Performance testing results demonstrated that the FIBERGRAFT ™ BG Morsels is substantially equivalent to the predicate device." and "device functions as intended without raising new safety or effectiveness questions compared to the previously cleared BG Morsels." |
2. Sample Size Used for the Test Set and Data Provenance
The document does not specify the sample sizes used for the "fluid absorbability," "packability," or "handling characteristics" tests. It also does not mention the country of origin or whether the data was retrospective or prospective. It only states "testing was conducted."
3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications
The document does not mention the use of experts or their qualifications for establishing ground truth for the performance testing. The "testing" appears to be focused on physical and material properties rather than clinical outcomes requiring expert interpretation.
4. Adjudication Method for the Test Set
The document does not describe any adjudication method. This type of physical/material testing typically does not involve adjudication as it's not based on subjective interpretation.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
The document does not describe an MRMC comparative effectiveness study. This type of study is typically done for diagnostic imaging devices where human readers interpret results with and without AI assistance. This device is a bone graft substitute, not an imaging AI.
6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study
The document does not describe a standalone algorithm performance study. This is not an AI device. The performance testing conducted was on the physical properties of the bone graft substitute.
7. Type of Ground Truth Used
For the performance assessment, the "ground truth" seems to be established physical/material property standards and the performance of the predicate device. The tests (fluid absorbability, packability, handling at time zero and after aging) are compared implicitly or explicitly against the known acceptable characteristics of the predicate and expected performance for a bone graft substitute.
8. Sample Size for the Training Set
This device is not an AI/ML device, so there is no concept of a "training set" in the context of machine learning. The term "training set" is not applicable here.
9. How the Ground Truth for the Training Set Was Established
Since there is no training set mentioned, this point is not applicable.
Ask a specific question about this device
(189 days)
BG MORSELS
BG Morsels - Bone Graft Substitute is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. BG Morsels is indicated to be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced with bone during the healing process.
BG Morsels is not indicated for use in load-bearing applications; therefore, standard internal or external stabilization techniques must be followed to obtain rigid stabilization.
BG Morsels provides an osteoconductive, resorbable, biocompatible bone graft substitute made from crystalline 45S5 bioactive glass. Each granule of BG Morsels is created from a matrix of bioactive glass fibers and microspheres. Bioactive glass is defined as a group of glasses which has a compositional range that allows the formation of hydroxyapatite (HA) as a surface laver when exposed to an aqueous phosphate-containing solution such as simulated body fluid. The HA layer that forms in an aqueous phosphate-containing solution plays a significant role in forming a strong bond with natural bone. The granules provide an ultra-porous scaffold for desired biological response and improved handling characteristics, while optimizing radiopacity and resorption. BG Morsels are generally spherical in appearance and provided in granular form. The matrix is flash sintered to form a porous shell at its surface, which creates the generally spherical structure of the granules, while maintaining a level of porosity within each granule.
Here's an analysis of the provided text regarding the acceptance criteria and study for the Prosidyan, Inc.'s BG Morsels - Bone Graft Substitute:
Acceptance Criteria and Device Performance for BG Morsels - Bone Graft Substitute
The acceptance criteria for the BG Morsels device are implicitly defined by its substantial equivalence claim to predicate devices (NovaBone Resorbable Bone Graft Substitute (K052494) and NovaBone Putty (K112773)) and its ability to function as intended for Class II bone void fillers. The performance data provided focuses on demonstrating safety and effectiveness comparable to these predicates.
1. Table of Acceptance Criteria and Reported Device Performance
Given that this is a 510(k) submission, explicit quantitative acceptance criteria (e.g., "must achieve X% new bone formation") are not directly stated in the summary. Instead, the acceptance is based on demonstrating comparable performance to legally marketed predicate devices.
Acceptance Criteria Category | Benchmark/Implicit Criteria | Reported Device Performance (BG Morsels) |
---|---|---|
Material Properties | Osteoconductive | Osteoconductive (made from 45S5 bioactive glass) |
Resorbable | Resorbable (replaced with bone during healing) | |
Biocompatible | Biocompatible (demonstrated by ISO 10993 testing and clinical history of bioactive glass) | |
Bioactivity | Bioactive (in vitro studies show apatite layer formation in SBF) | |
Mechanical/Physical | Functional as bone void filler | Provides ultra-porous scaffold, optimized radiopacity and resorption. Flash sintered for porous shell. |
Packaging integrity | Passed simulated distribution, whole package integrity, seal strength, accelerated and real-time aging tests. | |
Biological Performance (In Vivo) | New bone formation in critical size defects, comparable to predicate. | Demonstrated evidence of new bone formation in critical size defects. Performs as safely and effectively as predicate device (NovaBone Putty). No new safety or effectiveness concerns. |
Resorption and replacement by bone | Resorbs and is replaced with bone during healing process (as per intended use statement). | |
Safety | Safe for intended use | ISO 10993 biocompatibility, same chemical composition as predicate (long history of use), no new safety concerns raised by animal study. |
Effectiveness | Effective as a bone void filler | Performs as effectively as predicate device, consistent with FDA recommendations for Class II synthetic bone graft substitutes. |
2. Sample Size Used for the Test Set and Data Provenance
- Animal Study (In Vivo Test Set):
- Sample Size: "58 skeletally mature sheep"
- Data Provenance: "ovine model" (sheep), suggesting a prospective animal study. The country of origin of the study is not specified, but the submission is to the US FDA.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications
The text doesn't explicitly state the number of experts used for ground truth or their exact qualifications. However, the animal study involved "radiographic, histological, histomorphometric, and biomechanical data" analysis. This implies that experts in veterinary radiology, histology, histomorphometry, and biomechanics would have been involved in evaluating the outcomes. Common qualifications would include DVM/PhD with specialization in these areas, or relevant scientific/medical degrees and experience.
4. Adjudication Method for the Test Set
The document does not specify an adjudication method like 2+1 or 3+1 for the animal study data. It merely states that various types of data (radiographic, histological, histomorphometric, biomechanical) were collected and analyzed. It's common in animal studies for principal investigators and study pathologists to interpret results collectively or independently.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
No, an MRMC comparative effectiveness study was not done. The study described is an animal model comparing the device to a predicate and a sham control, not a human reader study evaluating improved performance with AI assistance.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
This question is not applicable as the BG Morsels is a physical medical device (bone graft substitute), not an algorithm or AI system. Therefore, standalone algorithm performance is not relevant. The performance evaluated is that of the physical device.
7. The Type of Ground Truth Used
- For the animal study (in vivo performance): The ground truth was established by direct experimental observation and quantitative measurements from the ovine model, including:
- Radiographic findings (imaging evidence of bone healing)
- Histological analysis (microscopic examination of tissue structure)
- Histomorphometric analysis (quantitative measurements from histology, e.g., new bone volume, defect fill)
- Biomechanical data (measurements of bone strength or stiffness).
- Comparison to a positive control (predicate device) and a negative control (untreated defect).
8. The Sample Size for the Training Set
This question is not applicable for this type of device. The BG Morsels is a physical medical device, not an AI or machine learning model that requires a "training set." The development process would involve material science, engineering, and preclinical testing, rather than data training.
9. How the Ground Truth for the Training Set Was Established
This question is not applicable as there is no "training set" in the context of this physical device.
Ask a specific question about this device
Page 1 of 1